Loading…
← CockpitCompetitor Analysis › ALKEM.NS Alkem LaboratoriesOpen in the cockpit ↗

Alkem LaboratoriesALKEM.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major

Indian branded-generics maker best known for anti-infective drugs, with a growing US generics and biosimilars business.

≈ India's mid-cap generics maker with a biosimilar armMomentum neutral 49
Mkt cap
$6.69B
US dollars, full cap
Free float
37%
of shares outstanding
$/day
$8.47M
20-day average traded
Fwd P/E
27.3×
forward earnings
ROIC−WACC
-0.8 pp
WACC 12.5%
Hurdle
+14 pp
Req g minus delivered
Next earnings
79 days
5 Feb 2027
Close · INR₹5,222
1D+0.9%
1W-4.1%
1M+4.4%
3M-4.6%
6M-4.5%
YTD-5.2%
1Y-9.4%
ATR %2.5%
Beta0.66
52w lowhigh12.0% off high

What Alkem Laboratories does

Indian branded-generics maker best known for anti-infective drugs, with a growing US generics and biosimilars business.

Earns most of its sales from branded medicines in India, sold through a very large field force of representatives to doctors and wholesalers, with anti-infectives and chronic treatments leading. The US generics arm and the biosimilar unit Enzene add exports. The founding Singh family controls it.

In one line: India's mid-cap generics maker with a biosimilar arm.

Products and services

  • India branded formulations (anti-infectives, Clavam)
  • US generics
  • Enzene Biosciences biosimilars
  • APIs

Customers

  • Indian retail pharmacies
  • US distributors

Where it sits in the supply chain

  • Pharmaceuticals
  • Branded generics (India)
  • US generics + biosimilars (Enzene)

What could go right

  • Domestic anti-infective/chronic brand growth
  • US generic launches

What could go wrong

  • Seasonal anti-infective demand swings
  • US pricing pressure

Moat: narrow (brand, distribution). Leading anti-infective brand (Clavam) and one of India's largest pharma sales forces.

Headquarters: Mumbai, India · Founded: 1973 · Employees: 23,386

Named competitors

Alkem Laboratories at a glance

Size Alkem Laboratories (ALKEM.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $6.69B, the 172nd largest of 1,066 India companies the cockpit tracks. Shares closed at ₹5,222 on 18 Nov 2026.

Performance Over six months the shares fell 4.5%, against -1.8% for the median peer and +3.8% for the India market (cap-weighted) — 10th lowest of 20 in its peer set.

Growth Revenue grew 12.5% over the last twelve months (peer median +16.4%); the operating margin is 17.3% (peer median 13.8%).

Valuation It trades at 27.3× forward earnings against a peer median of 17.3× (4th most expensive of 15).

Price implies For today's price to make sense, revenue must grow about 25% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 0.8 points below its cost of capital (12.5% WACC).

Next results Next results expected around 5 Feb 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026Peer median 99ALKEM.NS 96
Six months, rebased to 100: Alkem Laboratories against the median of its 20 peers (local-currency closes).

Alkem Laboratories financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹156B₹147B₹129B₹126B₹116B
Revenue growth—+13%+3%+8%—
Gross profit₹68.4B₹57.9B₹48.4B₹46.4B₹37.6B
EBITDA₹31.4B₹30.8B₹25.4B₹22.5B₹16.8B
Net income₹20.7B₹23.0B₹21.7B₹18.0B₹9.84B
Free cash flown/a₹15.5B₹15.0B₹18.4B₹15.1B
Capital expendituren/a₹6.17B₹6.76B₹2.59B₹2.33B
Total debt₹23.1B₹20.5B₹13.8B₹14.2B₹14.0B

Quarterly statements and history in the cockpit →

Alkem Laboratories competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-40%-20%0%+20%000963000999ORKA0126Z0BLTE9926BANBBIOCON6821688331IBRXCYTKCORTSUPNKNSAGRFLGNDALKEM.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Alkem Laboratories is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%20×40×60×000963000999APTXBANBBIOCON68216883314528CORTSUPNKNSALGNDALKEM.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Alkem Laboratories is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%100%200%300%000963000999688331CORTSUPNKNSALGNDALKEM.NSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Alkem Laboratories is the large dot.

Alkem Laboratories competitors and peer comparison

Head to head with its named competitors (ALKEM.NS vs MANKIND.NS vs CIPLA.NS vs TORNTPHARM.NS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Alkem Laboratories ALKEM.NS$6.69B-5%+13%17%27.3×25.0%
Mankind Pharma MANKIND.NS$11.6B+5%+13%21%44.4×28.6%
Cipla CIPLA.NS$12.2B+1%-1%13%29.1×28.4%
Torrent Pharmaceuticals TORNTPHARM.NS$18.8B+3%+42%22%70.2×37.6%
Lupin LUPIN.NS$9.67B-14%+24%24%21.0×8.8%

How Alkem Laboratories compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Alkem Laboratories against its 20 peers (data as of 18 Nov 2026)
MeasureALKEM.NSPeer medianRank in peer set
1-month return+4.4%-0.7%8th highest of 21
6-month return-4.5%-1.8%10th lowest of 20
Distance from 52-week high-12.0%-25.4%7th highest of 21
Revenue growth (TTM)+12.5%+16.4%9th lowest of 18
Operating margin17.3%13.8%6th highest of 19
Forward P/E27.3×17.3×4th most expensive of 15
Growth the price implies (Req g, 7 yrs)25.0%3.6%2nd most demanding of 11
Growth delivered (Del g)+10.7%+12.3%5th lowest of 11
Hurdle (Req g minus delivered)+14.3 pp-12.7 pp2nd most demanding of 11
ROIC minus cost of capital-0.8 pp+1.9 pp9th lowest of 18
EV / EBITDA20.5×21.0×5th cheapest of 10
Net debt / EBITDA0.3×0.8×4th least indebted of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Alkem Laboratories ALKEM.NSIndia$6.69B-5%+13%17%27.3×25.0%+10.7%
Huadong Medicine 000963.SZChina$6.69B-18%+2%9%12.5×-3.9%+5.3%
China Resources Sanjiu Medical & Pharmaceutical 000999.SZChina$6.59B+6%+4%14%13.2×-6.2%+18.4%
Apotex Health APTX.TOCanada$6.56Bn/a+4%32%19.3×-11.9%+4.2%
Oruka Therapeutics ORKAUnited States$6.49B+58%n/an/an/an/an/a
Samsung Epis 0126Z0.KSSouth Korea$6.49B-31%n/a12%23.8×n/an/a
Belite Bio, Inc. ADR BLTEUnited States$6.41B+9%n/an/an/an/an/a
Akeso 9926.HKHong Kong$7.01B-48%+42%-25%n/an/an/a
Bachem BANB.SWSwitzerland$7.06B0%+5%19%32.4×n/an/a
Biocon BIOCON.NSIndia$6.31B-15%+6%8%61.3×n/an/a
Asymchem Laboratories (Tianjin) 6821.HKHong Kong$7.10B+17%+24%17%24.4×n/an/a
RemeGen 688331.SSChina$6.28B-24%+272%61%10.8×1.1%+303.3%
ImmunityBio IBRXUnited States$7.13B-17%+121%-150%n/an/an/a
Cytokinetics CYTKUnited States$7.15B-35%+30%-625%n/an/an/a
ONO Pharmaceutical 4528.TJapan$7.33B-2%-2%22%15.3×-6.8%+10.8%
Mirum Pharmaceuticals MIRMUnited States$6.04B-5%+42%-21%n/an/an/a
Corcept Therapeutics CORTUnited States$7.42B+15%+30%12%15.3×23.9%+16.6%
Supernus Pharmaceuticals SUPNUnited States$6.02B-41%+16%45%8.0×6.2%+13.9%
Kiniksa Pharmaceuticals International KNSAUnited States$7.47B+75%+58%14%56.6×10.4%+45.5%
Grifols GRF.MCSpain$7.48B+19%+1%16%13.1×7.1%+7.1%
Ligand Pharmaceuticals LGNDUnited States$5.98B+37%+1%14%27.3×57.7%+7.5%

Questions

Who are Alkem Laboratories's main competitors?
Named competitors: Mankind Pharma (MANKIND.NS), Cipla (CIPLA.NS), Torrent Pharmaceuticals (TORNTPHARM.NS), Lupin (LUPIN.NS). The cockpit's measured peer set (industry) also includes Huadong Medicine (000963.SZ), China Resources Sanjiu Medical & Pharmaceutical (000999.SZ), Apotex Health (APTX.TO), Oruka Therapeutics (ORKA), Samsung Epis (0126Z0.KS), Belite Bio, Inc. ADR (BLTE).
Is Alkem Laboratories expensive compared with its peers?
On forward p/e it trades at 27.3× against a peer median of 17.3×, 4th most expensive of 15 in its peer set. For today's price to make sense, revenue must grow about 25% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is +14 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Alkem Laboratories stock performed?
Over six months to 18 Nov 2026 the shares returned -4.5% against -1.8% for the median peer; over one year -9.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.